Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Mult Scler J Exp Transl Clin ; 3(3): 2055217317727294, 2017.
Article in English | MEDLINE | ID: mdl-28856010

ABSTRACT

BACKGROUND: Netrin-1, a secreted laminin-related protein, is known to regulate not only axonal guidance and neuronal cell migration, but also blood-brain barrier integrity and inflammation. Two preliminary studies reported altered serum netrin-1 levels in multiple sclerosis; however, associations with longitudinal clinical and magnetic resonance imaging activity have not been investigated. OBJECTIVES: We aimed to assess serum netrin-1 in multiple sclerosis and controls with respect to disease activity and its temporal dynamics. METHODS: Serum netrin-1 was assessed by enzyme-linked immunosorbent assay in 79 patients with clinically isolated syndrome or multiple sclerosis, and 30 non-inflammatory neurological disease controls. In patients, serum samples were collected immediately prior to gadolinium-enhanced 3 T magnetic resonance imaging at two time points (initial contrast-enhancing gadolinium+ n = 47, non-enhancing gadolinium- n = 32; reference gadolinium- n = 70; median time-lag 1.4, interquartile range 1.0-2.3 years). RESULTS: Serum netrin-1 levels were similar in clinically isolated syndrome, multiple sclerosis and controls, and gadolinium+ and gadolinium- patients. Among gadolinium+ patients, serum netrin-1 was decreased in clinically active (n = 8) vs non-active patients (n = 39; p = 0.041). Serum netrin-1 showed no temporal dynamics in multiple sclerosis and was unrelated to clinical data. CONCLUSIONS: Serum netrin-1 levels show no multiple sclerosis specific changes and are not sensitive for detection of subclinical disease activity. Netrin-1 changes during relapses may deserve further examination.

2.
Mult Scler ; 22(12): 1560-1568, 2016 10.
Article in English | MEDLINE | ID: mdl-26762671

ABSTRACT

BACKGROUND: Lipocalin 2 (LCN2) may be involved in the immunopathogenesis of multiple sclerosis (MS) and might further impact on iron homoeostasis. Brain iron accumulates in MS; however, the association to iron-related proteins is still unsolved. OBJECTIVE: To investigate cerebrospinal fluid (CSF) and serum LCN2, transferrin (Trf) and ferritin in early MS in relation to disease evolution and longitudinal brain iron accumulation. METHODS: We analysed CSF and serum LCN2 by enzyme-linked immunosorbent assay (ELISA) and Trf and ferritin by nephelometry in 55 patients (45 clinically isolated syndrome (CIS), 10 MS, median clinical follow-up 4.8 years) and 63 controls. In patients, we assessed sub-cortical grey matter iron by 3T magnetic resonance imaging (MRI) R2* relaxometry (median imaging follow-up 2.2 years). RESULTS: Compared to controls serum (p < 0.01), CSF (p < 0.001) LCN2 and CSF Trf (p < 0.001) levels were reduced in the patients. CSF LCN2 correlated with CSF Trf (r = 0.5, p < 0.001). In clinically stable patients, CSF LCN2 levels correlated with basal ganglia iron accumulation (r = 0.5, p < 0.05). In CIS, higher CSF LCN2 levels were associated with conversion to clinically definite MS (p < 0.05). CONCLUSION: We demonstrate altered LCN2 regulation in early MS and provide first evidence for this to be possibly linked to both clinical MS activity and iron accumulation in the basal ganglia.


Subject(s)
Basal Ganglia/metabolism , Demyelinating Diseases/cerebrospinal fluid , Iron/metabolism , Lipocalin-2/cerebrospinal fluid , Multiple Sclerosis/cerebrospinal fluid , Adult , Basal Ganglia/diagnostic imaging , Demyelinating Diseases/blood , Demyelinating Diseases/diagnostic imaging , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multiple Sclerosis/blood , Multiple Sclerosis/diagnostic imaging
3.
Mult Scler ; 20(12): 1569-77, 2014 Oct.
Article in English | MEDLINE | ID: mdl-24777275

ABSTRACT

BACKGROUND: Previous magnetic resonance imaging (MRI) studies have demonstrated increased iron deposition in the basal ganglia of multiple sclerosis (MS) patients. However, it is not clear whether these alterations are associated with changes of iron metabolism in body fluids. OBJECTIVES: The purpose of this study was to investigate if iron metabolism markers in cerebrospinal fluid (CSF) and serum of clinically isolated syndrome (CIS) and MS patients differ from controls and how they relate to clinical and imaging parameters. METHODS: We analysed serum ferritin, transferrin and soluble transferrin-receptor and CSF ferritin and transferrin by nephelometry in non-anaemic CIS (n=60) or early MS (n=14) patients and 68 controls. In CIS/MS we additionally assessed the T2 lesion load. RESULTS: CSF transferrin was significantly decreased in CIS/MS compared to controls (p<0.001), while no significant differences were seen in serum. Higher CSF transferrin levels correlated with lower physical disability scores (r= -0.3, p<0.05). CSF transferrin levels did not correlate with other clinical data and the T2 lesion load. CONCLUSION: Our biochemical study provides evidence that altered iron homeostasis within the brain occurs in the very early phases of the disease, and suggests that the transporter protein transferrin may play a role in the increased iron deposition known to occur in the brain of MS patients.


Subject(s)
Homeostasis/physiology , Multiple Sclerosis/cerebrospinal fluid , Transferrins/cerebrospinal fluid , Adult , Age of Onset , Female , Humans , Iron/metabolism , Magnetic Resonance Imaging/methods , Male , Middle Aged , Multiple Sclerosis/metabolism , Multiple Sclerosis/pathology
4.
Mult Scler ; 19(4): 436-42, 2013 Apr.
Article in English | MEDLINE | ID: mdl-22917689

ABSTRACT

BACKGROUND: Axonal damage is considered a major cause of disability in multiple sclerosis (MS) and may start early in the disease. Specific biomarkers for this process are of great interest. OBJECTIVE: To study if cerebrospinal fluid (CSF) biomarkers for axonal damage reflect and predict disease progression already in the earliest stages of the disease, that is, in clinically isolated syndrome (CIS). METHODS: We assessed CSF levels of neurofilament heavy (NFH), neurofilament light (NFL) and N-acetylaspartate (NAA) in 67 patients with CIS and 18 controls with neuropsychiatric diseases of non-inflammatory aetiology (NC). Patients with CIS underwent baseline magnetic resonance imaging (MRI) at 3T, and a follow-up MRI after 1 year was obtained in 28 of them. RESULTS: Compared with NC, patients with CIS had higher NFH (p=0.05) and NFL (p<0.001) levels. No significant group differences were found for NAA. Patients' NFH levels correlated with physical disability (r=0.304, p<0.05) and with change in brain volume over 1 year of follow-up (r=-0.518, p<0.01) but not with change in T2 lesion load. CONCLUSION: Our results confirm increased neurofilament levels already in CIS being related to the level of physical disability. The association of NFH levels with brain volume but not lesion volume changes supports the association of these markers with axonal damage.


Subject(s)
Biomarkers/cerebrospinal fluid , Brain/pathology , Demyelinating Diseases/cerebrospinal fluid , Neurofilament Proteins/cerebrospinal fluid , Adult , Aspartic Acid/analogs & derivatives , Aspartic Acid/cerebrospinal fluid , Demyelinating Diseases/pathology , Female , Humans , Magnetic Resonance Imaging , Male
6.
Nervenarzt ; 74(8): 704-7, 2003 Aug.
Article in German | MEDLINE | ID: mdl-12904873

ABSTRACT

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, which is crucial for cholesterol biosynthesis, and are widely used as lipid-lowering agents. These drugs greatly reduce atherosclerosis and cardiovascular morbidity, which in the past was mainly attributed to their cholesterol-lowering properties. However, recent evidence suggests that statins are also potent immunomodulators. They exerted beneficial effects on animal models of experimental autoimmune encephalomyelitis and thus have therapeutic potential for multiple sclerosis. Their exact mechanism of action is still unclear. HMG-CoA-dependent effects and a direct effect on immune receptors are conceivable and are reviewed here.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Anticholesteremic Agents/therapeutic use , Cholesterol/immunology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Lovastatin/therapeutic use , Multiple Sclerosis/drug therapy , Adjuvants, Immunologic/metabolism , Anticholesteremic Agents/immunology , Cholesterol/metabolism , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/immunology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/metabolism , Lovastatin/immunology , Lovastatin/metabolism , Multiple Sclerosis/immunology , Multiple Sclerosis/metabolism
7.
Neurology ; 59(7): 990-7, 2002 Oct 08.
Article in English | MEDLINE | ID: mdl-12370451

ABSTRACT

BACKGROUND: Recent data suggest that statins may be potent immunomodulatory agents. In order to evaluate the potential role of statins as immunomodulators in MS, the authors studied their immunologic effects in vitro and compared them to interferon (IFN)beta-1b. METHODS: Peripheral blood mononuclear cells (PBMC) obtained from untreated or IFN beta-1-treated patients with relapsing-remitting MS or from healthy donors (HD) and T cells were stimulated with concanavalin A, phytohemagglutinin, or antibody to CD3 in the presence of lovastatin, simvastatin, mevastatin, IFN beta-1b, or statins plus IFN beta-1b. The authors analyzed proliferative activity of T cells and B cells, cytokine production and release, activity of matrix metalloproteinases (MMP), and surface expression of activation markers, adhesion molecules, and chemokine receptors on both T and B cells. RESULTS: All three statins inhibited proliferation of stimulated PBMC in a dose-dependent manner, with simvastatin being the most potent, followed by lovastatin and mevastatin. IFN beta-1b showed a similar effect; statins and IFN beta-1b together added their inhibitory potentials. Furthermore, statins reduced the expression of activation-induced adhesion molecules on T cells, modified the T helper 1/T helper 2 cytokine balance, reduced MMP-9, and downregulated chemokine receptors on both B and T cells. Besides strong anti-inflammatory properties, statins also exhibited some proinflammatory effects. CONCLUSIONS: Statins are effective immunomodulators in vitro that merit evaluation as treatment for MS.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Interferon-beta/therapeutic use , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Adjuvants, Immunologic/pharmacology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Cell Division/drug effects , Cell Division/immunology , Dose-Response Relationship, Drug , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Interferon beta-1a , Interferon beta-1b , Interferon-beta/pharmacology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Multiple Sclerosis, Relapsing-Remitting/immunology , Receptors, Chemokine/immunology , Receptors, Chemokine/metabolism , Statistics, Nonparametric , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/metabolism
8.
Ann Neurol ; 50(3): 286-92, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11558784

ABSTRACT

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is widely regarded as an autoimmune disorder, although the autoantigen remains unknown. In this study, the sera of 21 CIDP patients were examined by immunofluorescence for antimyelin activity and by Western blotting for binding to myelin proteins. Six sera contained anti-P0 immunoglobulin G antibodies, and four of these caused conduction block and demyelination following intraneural injection in experimental animals. Absorption with P0 protein eliminated the demyelinating activity. These results show that P0 is an autoantigen in some patients with CIDP. Since P0 possesses powerful adhesion properties and is largely responsible for myelin compaction, the demonstration of demyelination by human anti-P0 antibodies provides new insight into this important and common immunopathological process.


Subject(s)
Autoantigens/blood , Myelin P0 Protein/immunology , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/immunology , Animals , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Myelin P0 Protein/blood , Myelin Sheath/immunology , Myelin Sheath/pathology , Nerve Fibers, Myelinated/immunology , Nerve Fibers, Myelinated/pathology , Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/blood , Rats
9.
Mult Scler ; 7(1): 13-8, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11321187

ABSTRACT

Humoral immune responses to Chlamydia pneumoniae (C. pneumoniae) were studied in paired sera and cerebrospinal fluid (CSF) of patients with definite multiple sclerosis (MS) and other inflammatory and non-inflammatory neurological diseases. Seropositivity was not significantly different between these groups. However, C. pneumoniae-specific IgG titers were significantly higher in CSF of MS than in controls. Sixteen out of 52 seropositive MS patients (30.8%) showed intrathecal synthesis of C. pneumoniae-specific IgG but only one of 43 seropositive controls (2.3%). In MS, this was strongly associated with intrathecal synthesis of polyclonal IgG in 13/16 patients. However, these elevated C. pneumoniae antibody titers in CSF did not significantly correlate with disease duration, disease course, clinical or MRI disease activity, disability or presence of oligoclonal IgG in MS.


Subject(s)
Antibodies, Bacterial/immunology , Autoimmune Diseases/microbiology , Chlamydia Infections/immunology , Chlamydophila pneumoniae/isolation & purification , Immunoglobulin G/immunology , Multiple Sclerosis/microbiology , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/biosynthesis , Antibodies, Bacterial/blood , Antibodies, Bacterial/cerebrospinal fluid , Antibodies, Viral/blood , Antibodies, Viral/cerebrospinal fluid , Antibody Specificity , Autoimmune Diseases/blood , Autoimmune Diseases/cerebrospinal fluid , Autoimmune Diseases/etiology , Autoimmune Diseases/immunology , Cerebrospinal Fluid Proteins/biosynthesis , Chlamydia Infections/complications , Chlamydia Infections/epidemiology , Chlamydia Infections/microbiology , Chlamydophila pneumoniae/immunology , Chronic Disease , Female , Herpesvirus 4, Human/immunology , Humans , Immunoglobulin G/biosynthesis , Immunoglobulin G/blood , Immunoglobulin G/cerebrospinal fluid , Inflammation , Magnetic Resonance Imaging , Male , Measles virus/immunology , Middle Aged , Multiple Sclerosis/blood , Multiple Sclerosis/cerebrospinal fluid , Multiple Sclerosis/etiology , Multiple Sclerosis/immunology , Mumps virus/immunology , Nervous System Diseases/blood , Nervous System Diseases/cerebrospinal fluid , Nervous System Diseases/immunology , Prevalence , Seroepidemiologic Studies
10.
Prog Neurobiol ; 64(1): 35-49, 2001 May.
Article in English | MEDLINE | ID: mdl-11250061

ABSTRACT

Integrins, a subgroup of adhesion receptors, are transmembrane glycoproteins that mediate interactions between cytoplasm and the extracellular environment. These interactions influence, among others, events such as cell migration, proliferation, and differentiation. Differential expression of integrins is developmentally regulated in the peripheral nervous system (PNS) and is associated with crucial events in both physiological and pathological processes. Preliminary studies suggest that integrin expression influences neural crest cell migration, axonal outgrowth, and Schwann cell differentiation. Similarly, the abnormal expression of integrins or their ligands, is associated with degenerative, inflammatory, and malignant disorders of the PNS. Finally, integrins participate in the complex interactions that promote repair of the PNS. A better comprehension of the role of integrins in the PNS, their protein interactions and transducing signals is being achieved by selected biochemical and genetic experiments. Here we review a large bias of evidence suggesting the key functions for integrins in the PNS.


Subject(s)
Integrins/physiology , Peripheral Nervous System Diseases/physiopathology , Peripheral Nervous System/physiopathology , Animals , Cell Differentiation/physiology , Humans , Nerve Regeneration/physiology
13.
Trends Neurosci ; 23(7): 317-27, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10856942

ABSTRACT

Autoreactive B cells and antibodies can be detected in a variety of neurological diseases. Their causative role has been established in some disorders and they are obviously involved in the pathogenesis of others. Some mechanisms engendering B-cell autoimmunity in animal models have been shown to operate in humans. Factors that determine B-cell immune-response patterns and the effector pathways have been identified. B-cell responses to CNS-restricted autoantigens are governed by distinctive immune reactions. Evidence has accumulated that the CNS is a permissive and, under inflammatory conditions, even a B-cell-supporting micro-environment. Data from human and animal experiments have enhanced our understanding of B-cell physiology in health and neurological disease, which has relevant diagnostic and therapeutic implications.


Subject(s)
Autoantibodies/immunology , B-Lymphocytes/immunology , Central Nervous System/immunology , Nervous System Diseases/immunology , Animals , Humans
14.
Ann Neurol ; 47(6): 694-706, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10852535

ABSTRACT

A variety of cellular and humoral immunological abnormalities have been observed in multiple sclerosis (MS). In the past few years, several lines of evidence converged to imply an important role of autoreactive antibodies and B cells in the pathogenesis of MS. Recent data suggest that autoantibodies may be harmful in lesion formation but also potentially beneficial in repair. This review surveys recent advances in the concepts of generation and nature of pathogenetic autoantibodies, their potential modes of action, mechanisms of their long-term persistence, and the role of the inflamed brain tissue as a B-cell-supporting microenvironment in MS. Based on the presence of specific autoantibodies, it seems possible to define distinct MS subgroups in the near future. The therapeutic relevance of these new findings is presented.


Subject(s)
Autoantibodies/immunology , B-Lymphocytes/immunology , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Animals , Humans , Immunoglobulin G/immunology , Models, Immunological
15.
Int J Dev Neurosci ; 17(7): 715-25, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10568688

ABSTRACT

The present study describes the identification and partial characterization of a novel Schwann cell surface molecule by means of a monoclonal antibody (23E9). The 23E9 antigen was found in association with Schwann cells of the peripheral nerve but not with sensory neurons and satellite cells of the dorsal root ganglion. The expression of the antigen in the sciatic nerve starts after birth, is high around postnatal day 8 and becomes down-regulated towards the adult stage. This suggests that it may be involved in the induction of myelin formation. On Western blots, the antibody identified two major bands of approximately 27 and 42 kDa. Treatment of cultured Schwann cells with forskolin, an agent known to mimic neuronal contact in vitro, stimulated the up-regulation of the antigen. This implies that the expression of 23E9 is induced and maintained by axon-derived signals in vivo. Comparison of the presented data with the literature suggests that we have identified a novel cell surface molecule not previously characterized in the context of Schwann cell biology. To clarify the molecular identity of the antigen and define its physiological relevance, the antibody will be used in future studies for immunoprecipitation and functional in vitro assays.


Subject(s)
Aging/physiology , Antigens, Surface/genetics , Ganglia, Spinal/cytology , Schwann Cells/cytology , Schwann Cells/metabolism , Sciatic Nerve/cytology , Animals , Animals, Newborn , Antibodies, Monoclonal , Antibody Specificity , Antigens, Surface/analysis , Antigens, Surface/immunology , Cells, Cultured , Enzyme-Linked Immunosorbent Assay , Ganglia, Spinal/growth & development , Ganglia, Spinal/metabolism , Gene Expression Regulation, Developmental , Rats , Rats, Wistar , Sciatic Nerve/growth & development , Sciatic Nerve/metabolism
16.
Wien Klin Wochenschr ; 111(17): 728-37, 1999 Sep 17.
Article in English | MEDLINE | ID: mdl-10526397

ABSTRACT

The etiology of multiple sclerosis (MS) still remains elusive. However, the association of the disease with relevant genes, the characteristic white matter infiltrates, similarities with animal models, and the fact that MS can be treated with immunomodulatory and immunosuppressive therapies support the notion that this disorder is autoimmune in nature. During the last few years the knowledge about the mechanisms involved in the pathogenesis of MS increased rapidly. In this review, recent advances in our understanding about relevant pathomechanisms in inflammatory demyelinating diseases of the central nervous system will be discussed and the rational of some novel immunotherapies is explained in context of the current understanding of immunological principles.


Subject(s)
Autoimmunity , Immunotherapy/methods , Multiple Sclerosis , Cytokines/immunology , Humans , Immune Tolerance , Multiple Sclerosis/immunology , Multiple Sclerosis/pathology , Multiple Sclerosis/therapy , T-Lymphocytes/immunology , Vaccines
17.
Curr Opin Neurol ; 12(3): 323-36, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10499177

ABSTRACT

Multiple sclerosis is generally regarded to be a primarily T-cell driven disease. Recent evidence has refocused interest on antibodies. Adhesion molecules, matrix metalloproteinases, chemokines and cytokines, and nitric oxide and oxygen metabolites all participate in the amplification and effector stages of the disease.


Subject(s)
Multiple Sclerosis/immunology , Animals , Cell Adhesion Molecules/immunology , Chemokines/immunology , Cytokines/immunology , Humans , Metalloendopeptidases/immunology , Multiple Sclerosis/enzymology
18.
Brain Pathol ; 9(2): 343-60, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10219750

ABSTRACT

The peripheral nervous system (PNS) is a target for heterogenous immune attacks mediated by different components of the systemic immune compartment. T cells, B cells, and macrophages can interact with endogenous, partially immune-competent glial cells and contribute to local inflammation. Cellular and humoral immune functions of Schwann cells have been well characterized in vitro. In addition, the interaction of the humoral and cellular immune system with the cellular and extracellular components in the PNS may determine the extent of tissue inflammation and repair processes such as remyelination and neuronal outgrowth. The animal model experimental autoimmune neuritis (EAN) allows direct monitoring of these immune responses in vivo. In EAN contributions to regulate autoimmunity in the PNS are made by adhesion molecules and by cytokines that orchestrate cellular interactions. The PNS has a significant potential to eliminate T cell inflammation via apoptosis, which is almost lacking in other tissues such as muscle and skin. In vitro experiments suggest different scenarios how specific cellular and humoral elements in the PNS may sensitize autoreactive T cells for apoptosis in vivo. Interestingly several conventional and novel immunotherapeutic approaches like glucocorticosteroids and high-dose antigen therapy induce T cell apoptosis in situ in EAN. A better understanding of immune regulation and its failure in the PNS may help to develop improved, more specific immunotherapies.


Subject(s)
Peripheral Nervous System Diseases/immunology , Peripheral Nervous System/immunology , Animals , B-Lymphocytes/immunology , Humans , Inflammation , Macrophages/immunology , Models, Immunological , Peripheral Nervous System/pathology , Peripheral Nervous System Diseases/pathology , Peripheral Nervous System Diseases/physiopathology , T-Lymphocytes/immunology
19.
Trends Neurosci ; 22(1): 30-8, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10088997

ABSTRACT

Immune-mediated diseases of the CNS and PNS, such as multiple sclerosis and Guillain-Barré syndrome, respectively, constitute a major cause of transient and permanent neurological disability in the adult. The aetiology and pathogenesis of these disorders are only partially understood. On a cellular level, focal mononuclear-cell infiltration with demyelination and eventual axonal loss is a crucial pathogenetic event that leads to inflammation and subsequent dysfunction. Here, the evidence that integrins, a family of cell adhesion molecules, expressed on neural and immune cells might play a central role in immune cell recruitment to the CNS and PNS, and probably in tissue repair is reviewed. Distinct integrin expression patterns are observed in multiple sclerosis and Guillain-Barré syndrome. Therapeutic targeting of integrins has been very successful in the corresponding animal models and holds promise as a novel treatment strategy to combat human immune-mediated disorders of the nervous system.


Subject(s)
Immune System Diseases/physiopathology , Integrins/physiology , Nervous System Diseases/physiopathology , Animals , Autoimmune Diseases/physiopathology , Humans , Multiple Sclerosis/physiopathology , Neuritis/physiopathology , Polyradiculoneuropathy/physiopathology
20.
Muscle Nerve ; 22(1): 99-104, 1999 Jan.
Article in English | MEDLINE | ID: mdl-9883862

ABSTRACT

Charcot-Marie-Tooth type 1B (CMT 1B) disease, an inherited demyelinating peripheral neuropathy, results from different point mutations located in the P0 gene on chromosome 1 q21-23. We have quantified, at the ultrastructural level, the immunocytochemical expression of the P0 protein in two unrelated CMT 1B patients with mutations (Ser 78 to Leu and Asn 122 to Ser) located in two different exons in the extracellular domain of the protein. A twofold decrease in P0 expression was observed in compact myelin in each case, compared with age-matched controls. The severity of the phenotypes showed no direct relationship to the levels of P0 protein expression in these 2 patients.


Subject(s)
Charcot-Marie-Tooth Disease/metabolism , Myelin P0 Protein/biosynthesis , Amino Acid Substitution , Biopsy , Charcot-Marie-Tooth Disease/genetics , Charcot-Marie-Tooth Disease/physiopathology , Electrophysiology , Female , Humans , Immunohistochemistry , Middle Aged , Myelin Sheath/metabolism , Nerve Fibers/pathology , Neural Conduction/physiology , Point Mutation , Sural Nerve/metabolism , Sural Nerve/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...